Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Agonist Research Comparison

For laboratory and research use only. Not for human consumption.

Three compounds. Three generations of incretin science. And a pretty clear trajectory: every time researchers add another receptor target, the metabolic effects get bigger.

Semaglutide started it — a selective GLP-1 agonist that proved you could achieve serious weight reduction through a single receptor pathway. Then tirzepatide showed up and added GIP receptor activation on top. The results jumped. Now retatrutide (LY3437943) has entered the picture as the first triple agonist — GLP-1, GIP, and glucagon receptors all at once — and the phase 2 numbers are unlike anything published before in this field.

This guide breaks down all three. Receptor pharmacology, clinical data, pharmacokinetics, and where they actually differ in ways that matter for research design.

The Three Receptor Systems

Before the comparison means anything, you need the receptor map.

GLP-1 — The Foundation

Found in pancreatic islets, the brain, the gut, the cardiovascular system. Flip this receptor on: insulin goes up (glucose-dependent, not a blanket spike), glucagon gets suppressed, gastric emptying slows down, and the hypothalamus turns appetite down. All three compounds share this receptor. It’s the starting line.

GIP — The Amplifier

Beta cells, fat tissue, bone, brain. GIP cranks insulin secretion higher and does something in lipid metabolism and central appetite regulation that we’re still fully characterizing. Tirzepatide and retatrutide both activate GIP. Semaglutide skips it entirely. That one receptor difference? It accounts for a meaningful chunk of the gap between them.

Glucagon — The Liver Switch

Mostly hepatic. Activate glucagon receptors and the liver starts breaking down glycogen, making glucose, and — this is the key part — oxidizing fatty acids. Energy expenditure goes up. Lipids get burned. Only one compound in this comparison touches glucagon receptors: retatrutide. That’s what makes it a triple agonist, and it’s why researchers think it can drive liver fat reduction that dual agonists simply can’t (PMID: 37366315).

Semaglutide: The GLP-1 Standard

Thirty-one amino acids. 94% sequence homology to native GLP-1(7-36). An aminoisobutyric acid swap at position 8 blocks DPP-4 from cutting it apart, and a C-18 fatty diacid chain at position 26 lets it hitch a ride on albumin — stretching the half-life to about 165 hours. One injection per week.

What it does in humans: STEP-1 trial (PMID: 33567185), 2.4 mg subcutaneous weekly for 68 weeks. Average body weight change: −14.9%. Placebo: −2.4%. Roughly 86% of subjects hit at least 5% weight loss. Those numbers made headlines — and they should have. For a single-receptor agonist, that’s a strong ceiling.

Semaglutide also has cardiovascular outcomes data from the SELECT trial (PMID: 37952131), which gives it the most complete safety and efficacy profile of the three. If you need a well-characterized reference compound for incretin research, this is it.

Tirzepatide: Adding a Second Receptor

Thirty-nine amino acids built on a GIP backbone. But engineered to hit both GIP and GLP-1 receptors. A C-20 fatty diacid moiety handles the albumin binding, giving it a half-life around 5 days. Once weekly, like semaglutide. Molecular weight: about 4,813 Da.

Here’s what’s pharmacologically interesting about tirzepatide: the agonism is imbalanced. It hammers the GIP receptor — potency comparable to native GIP. But its GLP-1 receptor activity is about 5-fold weaker than native GLP-1. That biased profile isn’t a flaw. It’s a feature. The GIP-heavy, GLP-1-moderate balance appears to create metabolic effects you can’t get from pure GLP-1 agonism alone.

The data proves it. SURMOUNT-1 (PMID: 35658024): tirzepatide at 15 mg weekly for 72 weeks. Mean weight change: −20.9%. Placebo: −3.1%. Then came SURMOUNT-5 (DOI: 10.1056/NEJMoa2416394) — the study everyone was waiting for. Head-to-head against semaglutide at max tolerated doses over 72 weeks. Tirzepatide: −20.2%. Semaglutide: −13.7%. P<0.001. And 82% of tirzepatide subjects hit ≥10% weight loss compared to 60.5% on semaglutide.

Adding GIP to GLP-1 clearly does something. The question becomes: what happens when you add glucagon on top of that?

Retatrutide: The Triple Play

Same 39-amino acid length as tirzepatide. Same GIP backbone. Same C-20 fatty diacid for albumin binding. Half-life around 6 days. But retatrutide does something neither semaglutide nor tirzepatide can: it lights up glucagon receptors.

Why does that matter? Glucagon drives hepatic energy expenditure. Fatty acid oxidation in the liver. Direct lipid catabolism. The theory: while GLP-1 and GIP handle appetite and insulin, glucagon adds a whole second engine — one focused on the liver and thermogenesis.

The phase 2 data (PMID: 37366315) backed the theory up in a way nobody expected. 338 subjects with obesity. 48 weeks. Dose-dependent results:

• 1 mg: −8.7%
• 4 mg: −17.1%
• 8 mg: −22.8%
• 12 mg: −24.2%
• Placebo: −2.1%

At 8 and 12 mg, 100% of subjects lost at least 5% of body weight. Not 90%. Not 95%. Every single participant. And 83% on the 12 mg dose hit ≥15% reduction at just 48 weeks.

But the liver data is what really turned heads. In a NAFLD subset analysis, mean relative liver fat reduction exceeded 80% at the 8 and 12 mg doses. Over 90% of subjects in the highest group normalized their liver fat content. Those are numbers that no dual agonist has come close to matching. The glucagon component appears to be doing something unique in hepatic metabolism.

The Head-to-Head Numbers

Parameter	Semaglutide	Tirzepatide	Retatrutide
Type	Selective GLP-1 agonist	Dual GIP/GLP-1 agonist	Triple GIP/GLP-1/Glucagon agonist
Targets	GLP-1	GIP + GLP-1	GIP + GLP-1 + Glucagon
Peptide Length	31 amino acids	39 amino acids	39 amino acids
Backbone	GLP-1(7-36) analogue	GIP backbone	GIP backbone
Half-Life	~7 days	~5 days	~6 days
Dosing	Once weekly	Once weekly	Once weekly
Max Weight Loss	−14.9% (68 wk)	−20.9% (72 wk)	−24.2% (48 wk)
≥5% Weight Loss	86.4%	91%	100% (8–12 mg)
≥15% Weight Loss	~32%	~57%	83% (12 mg)
Liver Fat Reduction	Moderate	Moderate-significant	>80% relative (8–12 mg)
Landmark Study	STEP-1	SURMOUNT-1	Phase 2 (NEJM)
Status	Approved (Ozempic/Wegovy)	Approved (Mounjaro/Zepbound)	Phase 3 (TRIUMPH)

Look at the weight loss progression: −14.9% → −20.9% → −24.2%. And retatrutide hit that number at 48 weeks vs. the other two at 68-72 weeks. The trend is unmistakable. More receptors, more effect. Whether that holds through phase 3 remains to be seen — but the direction is clear.

How the Mechanisms Actually Differ

Semaglutide: One Pathway, Well-Characterized

Bind GLP-1 receptor. Activate adenylyl cyclase. cAMP goes up. PKA and Epac2 pathways fire in beta cells. Hypothalamic appetite circuits get suppressed. It works — the data proves it. But you’re running everything through one receptor. Desensitization is a real concern with chronic single-pathway activation, and there’s a metabolic ceiling when you can only pull one lever.

Tirzepatide: Two Pathways, Complementary

GIP receptor in adipose tissue handles lipid storage and mobilization. GIP in the brain may amplify the appetite suppression that GLP-1 delivers. Two signaling cascades feeding into the same metabolic outcome. The SURMOUNT-5 head-to-head data confirms the advantage: same timeline, same comparison, and tirzepatide beat semaglutide by about 6.5 percentage points on weight loss.

Retatrutide: Three Pathways, Additive Biology

Add glucagon to the mix and you unlock the liver. Glycogenolysis. Gluconeogenesis. Fatty acid oxidation. Thermogenesis. The insulin-stimulating effects of GLP-1 and GIP partially offset glucagon’s glucose-raising tendency, creating what ADA 2023 researchers described as the opportunity to “alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia.” For labs studying triple agonist biology, retatrutide is currently the only option.

Pharmacokinetic Details

Same trick, three variations. Every compound uses fatty acid conjugation to grab albumin and ride it through circulation. All three end up as once-weekly injectables. But dig into the specifics and they’re not identical:

Semaglutide lasts longest — roughly 165 hours in plasma. C-18 fatty diacid. With 94% GLP-1 homology, what you see pharmacodynamically is essentially pure GLP-1 receptor kinetics driving the bus.

Tirzepatide clears faster at about 120 hours. C-20 fatty diacid. The real story here isn’t the half-life — it’s the biased agonism. Heavy GIP activation, moderate GLP-1. That imbalance produces a pharmacodynamic fingerprint no pure GLP-1 compound can match.

Retatrutide sits in the middle at ~144 hours. Also C-20 fatty diacid. Phase 1 work (PMID: 36356032) confirmed dose-proportional exposure and showed appetite suppression kicking in at ≥0.3 mg. Triglycerides dropped. Branched-chain amino acids dropped. Fasting glucagon fell while insulin secretion rose.

Where Each Compound Fits in Research

Obesity and Metabolic Syndrome

If you’re chasing maximum weight reduction endpoints, retatrutide’s 48-week phase 2 data (−24.2%) beats both competitors — and did it in less time. Phase 3 TRIUMPH data will either confirm that advantage or contextualize it with larger sample sizes and longer follow-up.

Liver Fat and NAFLD

Retatrutide owns this space right now. More than 80% relative liver fat reduction. Over 90% normalization rates. The glucagon receptor component appears to be the X-factor. For NAFLD researchers, this is the most interesting compound to come along in years. See how it compares against dual agonists like mazdutide.

Cardiovascular Research

Semaglutide has the SELECT trial — real cardiovascular outcomes data from a completed, powered study. Tirzepatide’s SURMOUNT-MMO is still running, expected around 2027. For now, if your study needs a cardiometabolic reference compound with hard endpoint data, semaglutide is the pick.

Glycemic Control

Retatrutide’s type 2 diabetes phase 2 data (PMID: 37840095) showed HbA1c reductions of 1.3% to 2.0% with 4–12 mg over 36 weeks. Up to 82% of subjects hit ≤6.5% HbA1c. Those numbers beat the active comparator (dulaglutide 1.5 mg) in the same study. The staircase pattern holds: single agonist < dual agonist < triple agonist for glycemic outcomes.

Safety Across All Three

GI side effects dominate. Nausea, diarrhea, vomiting, constipation. All three compounds. Dose-related, mostly mild-to-moderate, concentrated during dose escalation. The specifics:

• Semaglutide: ~44% GI events at max dose. About 7% discontinued because of them (STEP-1)
• Tirzepatide: Similar GI profile. SURMOUNT-5 showed 2.7% discontinuation from GI events vs. 5.6% with semaglutide — actually fewer dropouts despite larger effects
• Retatrutide: Higher overall adverse event rates (73–94% at 8–12 mg vs. 70% placebo). Discontinuation: 6–16%. And a new finding — dose-dependent heart rate increases that peaked at 24 weeks and then declined (PMID: 37366315)

Important caveat: retatrutide’s safety data comes from a phase 2 trial. 338 subjects. 48 weeks. That’s a fraction of the exposure data available for semaglutide and tirzepatide. TRIUMPH phase 3 will fill in the picture.

Research Availability

All three from Loti Labs, lyophilized, ≥98% purity, third-party tested:

• Semaglutide 5mg — $99.99
• Tirzepatide 5mg — $99.99 | 10mg — $149.99
• Retatrutide 5mg — $119.99 | 10mg — $199.99 | 20mg — $299.99 | 30mg — $389.99

Reconstitution solution and peptide calculator available for protocol prep.

Conclusion

The pattern is hard to argue with. GLP-1 alone: −14.9%. Add GIP: −20.9%. Add glucagon: −24.2%. Each generation of receptor engagement produces larger metabolic effects, and retatrutide’s liver fat data suggests the glucagon component brings something to the table that dual agonism can’t replicate.

Semaglutide has the deepest evidence base and the cardiovascular outcomes data. Tirzepatide proved dual beats single in a head-to-head trial. Retatrutide may prove triple beats dual — but it needs phase 3 to confirm what phase 2 suggests.

For metabolic researchers, these aren’t competing compounds. They’re complementary tools targeting overlapping but distinct biology. Pick the one that matches your research question.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340. PMID: 35658024
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315
4. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. PMID: 37385280
5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. DOI: 10.1056/NEJMoa2416394
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
7. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 36356032

For laboratory and research use only. Not for human consumption.